Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on April 25, 2013. The report details the entry into a Material Definitive Agreement with PerkinElmer Health Sciences, Inc. The Company is a biotechnology firm focused on TrNA technology.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new strategic agreement.
Material Changes and Agreement Details
On April 25, 2013, Trovagene entered into a Research and Development Agreement with PerkinElmer. Key terms include:
- Collaboration: Joint design and validation of an assay to determine the risk for developing hepatocellular carcinoma (HCC) using Trovagene's TrNA technology.
- Payment Structure: PerkinElmer will make milestone payments to Trovagene.
- HCC Option: PerkinElmer received an exclusive option to obtain an exclusive royalty-bearing license for the HCC field, exercisable within 15 days of proof of principle completion.
- Other Fields Option: PerkinElmer received an exclusive option for other fields, exercisable within 15 days of HCC assay proof of principle completion.
- Right of First Refusal: If PerkinElmer does not exercise an option or negotiations fail, Trovagene must offer PerkinElmer the same terms before licensing to a third party for one year if the third-party terms are more favorable.
- TROV Option: Trovagene retains an option to license PerkinElmer's intellectual property under specific conditions, such as if PerkinElmer fails to exercise its options or if resulting licenses are non-exclusive.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or a discussion of general risks. The primary contingency is the successful negotiation of license agreements following the proof of principle work. If negotiations fail within 60 days, PerkinElmer may license inventions to third parties without further obligation to Trovagene.
Investor Verification Checklist
- Verify the exact milestone payment amounts and triggers, which are not disclosed in this summary.
- Confirm the timeline for the "proof of principle" work to determine when options become exercisable.
- Review the definition of "more favorable terms" in the right of first refusal clause.
- Assess the strategic value of the "TROV Option" regarding PerkinElmer's intellectual property.